In a move designed to shore up its sagging vascular brachytherapy (VBT) sales, which have been ravaged by the drug-eluting stent (DES) phenomenon, Novoste (Norcross, Georgia) said in an earnings conference call last month that it had signed an agreement with Guidant (Indianapolis, Indiana) to facilitate a transition to Novoste products by existing customers of Guidant’s vascular brachytherapy system in the U.S. and Canada.